ReviewBiomedical engineering online2025
Application and prospects of lung organ-on-a-chip in the development of new drugs.
Review in Biomedical engineering online, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Respiratory disease, such as lung cancer, is a major risk factor that seriously endangers human health. In the development of new drugs, conventional preclinical and clinical testing stages rely on cell culture and animal experiment. However, the two methods may fall short of fully representing human biology, thereby presenting an opportunity to advance technological innovation. In this review, we focus on the structure and the composition of supporting cells of organ-on-a-chip (OOAC), whose most notable feature is its biomimetic representation of the human body. Its core advantage lies in its biomimetic human structure, which enables broad application scenarios in the field of pulmonary diseases including lung cancer, pneumonia, pulmonary edema, and pulmonary embolism. Finally, this review summarizes the current challenges and prospects of OOAC, highlighting its vast potential for advancement.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.